Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer

BACKGROUND: Endocrine therapy remains the mainstay of treatment for estrogen receptor-positive (ER+) breast cancer. Constitutively active mutations in the ligand binding domain of ERα render tumors resistant to endocrine agents. Breast cancers with the two most common ERα mutations, Y537S and D538G,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lainé, Muriel, Fanning, Sean W., Chang, Ya-Fang, Green, Bradley, Greene, Marianne E., Komm, Barry, Kurleto, Justyna D., Phung, Linda, Greene, Geoffrey L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117302/
https://www.ncbi.nlm.nih.gov/pubmed/33980285
http://dx.doi.org/10.1186/s13058-021-01431-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117302/
https://www.ncbi.nlm.nih.gov/pubmed/33980285
http://dx.doi.org/10.1186/s13058-021-01431-w

Ejemplares similares